The high transduction efficiency of JCPyV VLPs, combined with the lung cancer–specific expression of an SP-B promoter–driven suicide gene, is likely to enhance the efficacy of lung cancer gene therapy and reduce off-target toxicity. Here, SFTPB is linked to lung cancer.